Labcorp (NYSE:LH) Releases FY 2026 Earnings Guidance

Labcorp (NYSE:LH) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 18.100-18.550 for the period, compared to the consensus EPS estimate of 17.990. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Analysts Set New Price Targets

Several brokerages have issued reports on LH. Robert W. Baird lifted their target price on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings upgraded shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Bank of America boosted their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $315.33.

Labcorp Stock Performance

NYSE LH opened at $307.07 on Thursday. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $315.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The stock’s fifty day moving average is $272.53 and its two-hundred day moving average is $270.29. The firm has a market capitalization of $25.18 billion, a P/E ratio of 27.20, a price-to-earnings-growth ratio of 2.09 and a beta of 0.89.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts anticipate that Labcorp will post 18 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s payout ratio is 25.51%.

Insider Activity

In related news, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the transaction, the chief executive officer owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares in the company, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 6,991 shares of company stock valued at $1,796,696. Company insiders own 0.84% of the company’s stock.

Institutional Trading of Labcorp

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in shares of Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after buying an additional 289,029 shares in the last quarter. Marshall Wace LLP raised its holdings in Labcorp by 79.1% in the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock valued at $178,996,000 after acquiring an additional 275,454 shares in the last quarter. Millennium Management LLC raised its holdings in Labcorp by 2,491.3% in the fourth quarter. Millennium Management LLC now owns 277,323 shares of the medical research company’s stock valued at $69,575,000 after acquiring an additional 266,621 shares in the last quarter. Woodline Partners LP lifted its stake in Labcorp by 598.1% in the third quarter. Woodline Partners LP now owns 287,146 shares of the medical research company’s stock worth $82,428,000 after acquiring an additional 246,014 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Labcorp by 19.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,287,177 shares of the medical research company’s stock worth $322,927,000 after acquiring an additional 213,136 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.